AACR: Three Promising Anticancers From Loxo Oncology, Ignyta And BeiGene
This article was originally published in Scrip
Investigational anticancer drugs aimed at new potential targets, particularly those involving genetic abnormalities that can be identified for diagnostic purposes, were the focus of presentations on their safety and efficacy in Phase I studies at this year's American Association for Cancer Research (AACR) meeting, being held in New Orleans on Apr. 16-20.
Register for our free email digests: